https://orcid.org/0009-0003-1332-7563
-
Views
-
Cite
Cite
Xiuyan Gao, Ningning Fu, Qi Ben, Xiumei Bu, A Meta-Analysis of the Effects of Gut Microbiota–Based Interventions on Gastrointestinal and Behavioral Symptoms in Children With Autism Spectrum Disorder, Nutrition Reviews, 2025;, nuaf050, https://doi.org/10.1093/nutrit/nuaf050
Close - Share Icon Share
Abstract
Despite an increasing body of research showing gut microbiota–based interventions can improve gastrointestinal (GI) symptoms and behavioral symptoms in both humans and animals, there are still disagreements about its impact on autism spectrum disorder (ASD) in children.
The goal of this systematic review and meta-analysis was to fully investigate the effects of gut microbiota–based interventions (eg, fecal microbiota transplantation, probiotics, prebiotics) on GI and behavioral symptoms in children with ASD.
The PubMed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure, and Scopus databases were searched from inception to August 25, 2024.
Data were extracted by 2 reviewers independently, and discrepancies in authors’ judgments were resolved by discussion or consulting a third author.
The scale score of GI and behavioral symptoms before and after the intervention was extracted from included trials to evaluate the therapeutic effects of gut microbiota–based therapy in children with autism.
A total of 5722 records were identified, of which 13 included in narrative synthesis and 8 studies included a meta-analysis. The nonsignificant overall effect size of gut microbiota–based intervention on GI symptoms (standardized mean difference [SMD] = –0.34 [95% CI, –0.76 to 0.07]; P = .11) and behavioral symptoms (SMD = –0.18 [95% CI, –0.37 to 0.02]; P = .08) was observed. Nevertheless, we observed a significant effect size on behavioral symptoms in the subgroup of the intervention duration (SMD = –0.26 [95% CI, –0.49 to –0.03]; P = .02).
In children with autism, the proof supporting the validity of gut microbiota–based intervention on GI and behavioral symptoms should be interpreted cautiously. More randomized controlled trials with rigorous methodological quality are required to precisely confirm the curative benefits of gut microbiota–based interventions on GI and behavioral symptoms in children with autism.
PROSPERO registration no. CRD42024583213.
